
(Reuters) - Gilead Sciences Inc will buy Canada's YM BioSciences Inc for about $465 million to gain access to its blood and immune cell disorder drugs.
Gilead said it will pay $2.95 per YM share.
YM shares closed at C$1.66 on Tuesday on the Toronto Stock Exchange.
(Reporting by Adithya Venkatesan and Shounak Dasgupta in Bangalore; Editing by Roshni Menon)












